CD274 and non-small cell lung carcinoma: In January 2019, pembrolizumab in combination with chemotherapy was approved and reimbursed for 1L treatment of advanced NSCLC, regardless of PD-L1 expression level, based on Keynote-189 and Keynote-407 (11, 19–24).